Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Finance

Annovis Bio
Finance

Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise

November 19, 2025November 17, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported third-quarter 2025 financial results and detailed a series of clinical, operational, and intellectual-property developments that the company says position its lead …

Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise Read More

Palvella Therapeutics
Finance

Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly

November 18, 2025November 17, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported third-quarter results and detailed an intensifying slate of clinical milestones as its QTORIN platform advances across four rare dermatologic diseases — …

Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly Read More
Trinseo
Finance

Trinseo’s Deeper Loss Spurs Aggressive Cuts as Demand Weakens Again

November 18, 2025November 16, 2025 - by Timothy Alexander

WAYNE, PA — Trinseo (NYSE: TSE) reported another challenging quarter as soft global demand, pricing pressure in Europe, and lower equity income weighed heavily on results, pushing the specialty materials …

Trinseo’s Deeper Loss Spurs Aggressive Cuts as Demand Weakens Again Read More

Bentley Systems, Incorporated
Finance

Bentley’s Big AI Bet: What’s Fueling the Software Maker’s Surging Momentum?

November 16, 2025November 14, 2025 - by Timothy Alexander

EXTON, PA — Bentley Systems, Incorporated (Nasdaq: BSY) delivered another quarter of steady growth and widening profitability, reporting strong third-quarter 2025 results that reflect durable demand for its infrastructure engineering …

Bentley’s Big AI Bet: What’s Fueling the Software Maker’s Surging Momentum? Read More
Radian
Finance

Radian’s Bold Shake-Up Raises Big Questions About Its Future Direction

November 16, 2025November 14, 2025 - by Timothy Alexander

WAYNE, PA — Radian Group Inc. (NYSE: RDN) reported third-quarter 2025 results that reflect both steady financial performance and one of the most consequential strategic pivots in the company’s history. …

Radian’s Bold Shake-Up Raises Big Questions About Its Future Direction Read More

QVC Group
Finance

QVC Group Reports Steep Earnings Decline as Revenue and Margins Tighten

November 14, 2025November 12, 2025 - by Timothy Alexander

WEST CHESTER, PA — QVC Group, Inc. (Nasdaq: QVCGA, QVCGP; OTCQB: QVCGB) reported a sharp decline in profitability for the third quarter of 2025, as the company continues to navigate …

QVC Group Reports Steep Earnings Decline as Revenue and Margins Tighten Read More
Ecovyst
Finance

Ecovyst Reports Strong Q3 Growth, Moves to Streamline Portfolio With $556M Sale

November 14, 2025November 12, 2025 - by Timothy Alexander

WAYNE, PA — Ecovyst Inc. (NYSE: ECVT) reported higher third-quarter 2025 revenue and adjusted earnings as it moves to streamline its operations through the planned sale of its Advanced Materials …

Ecovyst Reports Strong Q3 Growth, Moves to Streamline Portfolio With $556M Sale Read More

Teleflex Incorporated
Finance

Teleflex Posts Strong Third-Quarter Revenue Growth and Declares Quarterly Dividend

November 13, 2025November 11, 2025 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) reported solid third-quarter 2025 financial results, highlighting continued growth across its global operations while announcing a new quarterly cash dividend.

Teleflex Posts Strong Third-Quarter Revenue Growth and Declares Quarterly Dividend Read More
Vishay Intertechnology
Finance

Vishay Books $790.6M in Q3 as Recovery Builds; Margin Hit From Newport

November 12, 2025November 11, 2025 - by Timothy Alexander

MALVERN, PA — Vishay Intertechnology, Inc. (NYSE: VSH) reported third-quarter 2025 revenue of $790.6 million, reflecting steady demand in smart-grid infrastructure, AI power, automotive, and aerospace/defense as markets gradually recover.

Vishay Books $790.6M in Q3 as Recovery Builds; Margin Hit From Newport Read More
Ocugen
Finance

Ocugen Advances Gene Therapy Pipeline as Phase 3 Trials Near Key Milestones

November 12, 2025November 11, 2025 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported third-quarter 2025 financial results and provided an update on its advancing portfolio of late-stage gene therapies for inherited retinal diseases. The biotechnology …

Ocugen Advances Gene Therapy Pipeline as Phase 3 Trials Near Key Milestones Read More

Posts pagination

Previous 1 … 3 4 5 … 21 Next

Trending News

  • REWIRE Act Targets Faster Grid Upgrades as Demand Surges

  • Senate Revives Rail and SNAP Safety Bills

  • Health Inspectors Cite Violations at 2 Food Sites

  • Masked Carjacking Ends in Guilty Plea

  • West Goshen: Where the Past Still Shapes the Pace

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Court News

Masked Carjacking Ends in Guilty Plea

13 hours ago21 hours ago

Arrested

Masked Gunmen Accused in Social Media Watch Robbery

14 hours ago21 hours ago

Aldo Funari II

Driver Accused of Pepper Spraying Man at Newark Wawa

17 hours ago21 hours ago

Copyright © 2026 MyChesCo.